CSC Technology & Digital Applications 3 — Questions and Answers
Question 1: Which remote monitoring feature of implantable cardioverter-defibrillators (ICDs) has been shown in clinical trials to reduce cardiovascular hospitalizations?
- Daily device self-tests with monthly physician review
- Automatic wireless transmission of device alerts and diagnostics (Correct answer)
- Weekly patient-initiated telephone transmissions
- Scheduled quarterly in-office interrogations without remote access
Correct answer: Automatic wireless transmission of device alerts and diagnostics
Automatic wireless transmission enables earlier detection of device alerts and clinical deterioration, reducing time to clinical action and hospitalization rates.
Question 2: During cardiac resynchronization therapy (CRT) optimization, which parameter adjustment has the strongest evidence for improving clinical outcomes?
- Rate response sensitivity based on accelerometer thresholds
- AV delay optimization using echocardiographic or device-based methods (Correct answer)
- Upper rate limit programming to prevent mode switching
- Shock energy titration based on defibrillation threshold testing
Correct answer: AV delay optimization using echocardiographic or device-based methods
Optimizing the AV delay maximizes ventricular filling time and interventricular synchrony, improving cardiac output and CRT response.
Question 3: An implantable loop recorder (ILR) is MOST appropriate for which clinical scenario?
- Monitoring known persistent atrial fibrillation burden during cardioversion
- Evaluation of unexplained recurrent syncope after non-diagnostic short-term monitoring (Correct answer)
- Continuous rhythm monitoring for 48 hours after ablation
- Detecting QTc prolongation in a patient on antiarrhythmic therapy
Correct answer: Evaluation of unexplained recurrent syncope after non-diagnostic short-term monitoring
ILRs provide continuous monitoring for up to 3 years and are the preferred tool when shorter monitoring has failed to capture unexplained syncope.
Question 4: A patient with a subcutaneous ICD (S-ICD) develops hemodynamically stable, sustained monomorphic ventricular tachycardia at 160 bpm. The S-ICD CANNOT deliver which therapy?
- High-energy defibrillation shock
- Synchronized cardioversion shock
- Anti-tachycardia pacing (ATP) (Correct answer)
- Committed shock after rhythm redetection
Correct answer: Anti-tachycardia pacing (ATP)
The S-ICD lacks transvenous leads and therefore cannot deliver anti-tachycardia pacing, which requires intracardiac pacing capability.
Question 5: Which ambulatory cardiac monitoring modality maximizes the likelihood of correlating patient symptoms with an ECG rhythm in a patient with weekly palpitations?
- 24-hour Holter monitor
- Patch-based extended Holter monitor worn for 2–4 weeks (Correct answer)
- Single-lead consumer smartwatch ECG activated by the patient
- Standard 12-lead ECG performed in the clinic
Correct answer: Patch-based extended Holter monitor worn for 2–4 weeks
Extended Holter patch monitors provide continuous multi-week recording, maximizing the probability of capturing symptomatic events that occur less than daily.
Question 6: The CHAMPION trial demonstrated that remote pulmonary artery pressure monitoring using an implantable sensor (CardioMEMS) primarily reduced which outcome in heart failure patients with NYHA class III symptoms?
- All-cause mortality at 6 months
- Heart failure–related hospitalizations (Correct answer)
- Need for advanced therapies such as LVAD or transplantation
- Rate of sudden cardiac death
Correct answer: Heart failure–related hospitalizations
The CHAMPION trial showed a 28% reduction in heart failure hospitalizations through hemodynamic-guided therapy adjustments based on daily PA pressure readings.
Question 7: When counseling a patient with a non–MRI-conditional pacemaker about electromagnetic interference, the minimum recommended distance between the device and a strong consumer magnet is approximately:
- 6 inches (15 cm) (Correct answer)
- 18 inches (45 cm)
- 36 inches (90 cm)
- 60 inches (150 cm)
Correct answer: 6 inches (15 cm)
Most device manufacturers recommend at least 6 inches (15 cm) of separation from magnets to prevent reversion to asynchronous pacing or sensing inhibition.
CSC Technology & Digital Applications 3
Which remote monitoring feature of implantable cardioverter-defibrillators (ICDs) has been shown in clinical trials to reduce cardiovascular hospitalizations?